A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

Inclusion Criteria: * Signed consent/parental consent and patient assent for minor children obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Patient has been diagnosed with Idiopathic Short Stature (ISS) and received at least 1 year of GH therapy. * Patient was prepubertal at initiation of and throughout first year of GH therapy, as determined by the treating physician and patient medical records. * Patient had no prior exposure to growth promoting therapy prior to initiation of GH therapy, including but not limited to growth hormone, IGF-I and ghrelin analogues. * Age at initiation of GH therapy: * Boys: Age above or equal to 3 years and below 11.0 years. * Girls: Age above or equal to 3 years and below 10.0 years. * Impaired height prior to initiation of GH therapy defined as at least 2 standard deviations below the mean height for chronological age and sex according to local growth reference charts. In the absence of local reference charts, the standards of Centres for Disease Control and Prevention should be used. * GH deficiency has been excluded via GH stimulation test (cut point of 7 nanograms per milliliter \[ng/ml\]) or other clinical and biochemical criteria according to local clinical practice. * Patient fits within one of the following response groups: * Change in Height Standard Deviation Score (SDS) after approximately the first year (+/- 2 months) of GH t…